Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02432625 · ClinicalTrials.gov registry record
BBD Longitudinal Study of Osteogenesis Imperfecta
A clinical trial of Osteogenesis Imperfecta, sponsored by Baylor College of Medicine.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 12
- Study locations
NCT02432625: Recruiting study of Osteogenesis Imperfecta, sponsored by Baylor College of Medicine.
NCT02432625 is a study of Osteogenesis Imperfecta that is actively recruiting participants, run by Baylor College of Medicine. The registered enrollment target is 1,000 participants, above the 84-participant average among 13 other Osteogenesis Imperfecta trials with a reported enrollment target (1090% higher). The trial reports 12 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02432625, a study of Osteogenesis Imperfecta, is actively recruiting participants, sponsored by Baylor College of Medicine.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 12
- Study locations
Study Summary
Osteogenesis Imperfecta (OI) is a rare disorder of increased bone fragility characterized by fractures with minimal or absent trauma, dentinogenesis imperfecta (DI), and, in adult years, hearing loss. It is seen in both genders and all races. The clinical features of OI represent a continuum varying from perinatal lethality to individuals with severe skeletal deformities, mobility impairments, and very short stature to nearly asymptomatic individuals with a mild predisposition to fractures, normal stature, and normal lifespan. Fractures can occur in any bone, but are most common in the extremities. These disorders can be devastating and progressive and result in deformity, chronic pain, impaired function and loss of quality of life. The overall goal of this study is to answer specific question about the natural history of brittle bone diseases as defined by molecular etiology and to develop the foundation for prospective clinical studies.
Primary Outcome
The molecular basis of the brittle bone disease will be correlated with phenotype, disease progression and response to current standard of care therapies.
Conditions Studied
Study Locations (12)
Arizona
- Phoenix Children's Hospital - Phoenix
California
- University of California Los Angeles - Los Angeles
Delaware
- AI Dupont Hospital for Children - Wilmington
District of Columbia
- Children's National Medical Center - Washington D.C.
Florida
- University of South Florida - Tampa
Maryland
- Kennedy Krieger Institute / Hugo W. Moser Research Institute - Baltimore
Nebraska
- University of Nebraska Medical Center - Omaha
New York
- Hospital for Special Surgery - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2015-06-01 |
| Est. Completion | 2031-12-31 |
What NCT02432625 shows while recruiting
NCT02432625 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 84-participant average among 13 other Osteogenesis Imperfecta trials with a reported enrollment target (1090% higher).
The record links to 1 condition, with Osteogenesis Imperfecta appearing as the primary indexed condition, and to 0 interventions.
NCT02432625 lists 12 locations in 12 states (Arizona, California, Delaware).
Frequently Asked Questions
What is clinical trial NCT02432625 about?
NCT02432625 is a clinical study titled "BBD Longitudinal Study of Osteogenesis Imperfecta". Osteogenesis Imperfecta (OI) is a rare disorder of increased bone fragility characterized by fractures with minimal or absent trauma, dentinogenesis imperfecta (DI), and, in adult years, hearing loss. It is seen in both genders and all races. The clinical features of OI represent a continuum varying...
What is the current status of trial NCT02432625?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2015-06-01. Estimated completion is 2031-12-31.
What conditions does trial NCT02432625 study?
This clinical trial studies the following conditions: Osteogenesis Imperfecta.
Who is sponsoring clinical trial NCT02432625?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02432625 being conducted?
This trial has 12 study locations across Arizona, California, Delaware, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteogenesis Imperfecta
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02432625's enrollment target sits among peer trials
1,000 1st of 13 higher than 13 of 13 other Osteogenesis Imperfecta trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteogenesis Imperfecta trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta
RECRUITING · Phase 3
-
Effects of Bisphosphonates on OI-Related Hearing Loss
RECRUITING · Phase 4
-
Setrusumab vs Placebo for Osteogenesis Imperfecta
ACTIVE NOT RECRUITING · Phase 2
-
Urinary Biomarkers of OI Pathobiology
ACTIVE NOT RECRUITING
-
Clear Aligners for the Treatment of Dental Malocclusion in OI
ACTIVE NOT RECRUITING · NA
-
Cardiopulmonary Outcomes in Osteogenesis Imperfecta: BBD7708
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI